Publications

5808 Results

Intergroup pilot study of preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by capecitabine-based chemoradiation (CRT) for borderline resectable (BLR) pancreatic cancer (PDAC): initial results from Alliance Trial A021101

Authors
MHG Katz;Q Shi;SA Ahmad;J Herman;R Marsh;E Collisson;L Schwartz;H Kindler;AM Lowy;AP Venook
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr 4008); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), oral;
Year
2015
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/A021101

SWOG S0809: A phase II intergroup trial of adjuvant capecitabine/gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma

Authors
E Ben-Josef;K Guthrie;A El-Khoueiry;C Corless;M Zalupski;A Lowy;CR Thomas;SR Alberts;L Dawson;K Micetich;M Thomas;A Siegel;C Blanke
Journal / Conference
Journal of Clinical Oncology Aug 20;33(24):2617-2622
Year
2015
Research Committee(s)
Gastrointestinal
PMID
PMID25964250
PMC
PMC4534524
Study Number(s)
S0809

Safety and tolerability of the combination of ATRA + Arsenic Trioxide (ATO) + Gemtuzumab Ozogamicin (GO) in high-risk acute promyelocytic leukemia (APL): initial report of the SWOG/Alliance/ECOG S0535 trial (NCT00551460)

Authors
J Lancet;M Othus;R Komrokji;S Coutre;D DeAngelo;M Tallman;M Litzow;F Appelbaum
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr 7016); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster discussion;
Year
2015
Research Committee(s)
Leukemia
Study Number(s)
S0535

Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients treated on SWOG S0703 (NCT00658814)

Authors
S Nand;N Achille;M Othus;K Phelan;S Zhang;K Cooper;J Godwin;F Appelbaum;J Radich;H Erba;N Zeleznik-Le
Journal / Conference
Journal of Clinical Oncology J Clin Oncol 33:5s (suppl; abstr 7060); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster;
Year
2015
Research Committee(s)
Leukemia
Study Number(s)
S0703

SWOG S0820/PACES (Preventing Adenomas of the Colon with Eflornithine and Sulindac), A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial - NCT01349881

Authors
J Zell;J Unger;G Anderson;E Cook;J Krouse;P Lance;L Minasian;L Ford;P Brown
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr TPS3627); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster session;
Year
2015
Research Committee(s)
Prevention, Screening, and and Surveillance
Study Number(s)
S0820

SWOG S1320: A randomized phase II trial of intermittent versus continuous dosing of dabrafenib and trametinib in BRAFV600E/K mutant melanoma

Authors
A Algazi;M Othus;A Daud;J Mehnert;C Lao;R Kudchadkar;K Grossmann;R Lo;J Moon;J Kirkwood;A Ribas
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr TPS9093); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster session;
Year
2015
Research Committee(s)
Melanoma
Study Number(s)
S1320

SWOG S1404: A phase III randomized trial comparing high dose interferon to MK-3475 (pembrolizumab) in patients with high risk resected melanoma

Authors
K Grossmann;M Othus;A Tarhini;S Patel;J Moon;V Sondak;J Kirkwood;A Ribas
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr TPS9085); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster session;
Year
2015
Research Committee(s)
Melanoma
Study Number(s)
S1404

SWOG S9005: double blind phase III randomized trial of the anti-progestin agent mifepristone in the treatment of unresectable meningioma

Authors
H Ji;C Rankin;S Grungerg;J Ahmadi;L Feun;R Fredericks;C Russell;F Kabbinavar;K Stelzer;A Schott;C Verschraegen
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr e17084); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), publication only;
Year
2015
Research Committee(s)
Brain
Study Number(s)
SWOG-9005

Long term consequences of intermittent and continuous androgen deprivation in patients with metastatic prostate cancer

Authors
D Hershman;JM Unger;J Wright;S Ramsey;C Till;C Tangen;W Barlow;C Blanke;IM Thompson;M Hussain
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr 5008); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), oral presentation;
Year
2015
Research Committee(s)
Genitourinary
Study Number(s)
SWOG-9346

Creating a national collaborative strategy to enhance trial accrual in NCI’s National Clinical Trials Network (NCTN) in the era of precision medicine

Authors
A Denicoff;G Schroer;H Massett;R Bangs;J Berlin;M Bischoff;F Desanto;A Duli;S Hartson-Stine;E Horvath;R Lambersky;M Katz;S Ramalingam;W Williams;N Seibel;W McCaskill-Stevens;M Mooney;J Abrams
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr LBA500); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster session;
Year
2015
Research Committee(s)
Cancer Care Delivery